Below is the press release from the FDA on approval for Medivation (Nasdaq: MDVN) and Astellas' Xtandi for late stage ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE